New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07284992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial compares two types of radiotherapy (short-course vs long-course) given alongside immunotherapy (Adebrelimab) and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see which approach leads to a higher rate of complete tumor disappearance. About 208 participants will be randomly assigned to one of the two treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (PD-L1 inhibitor) plus capecitabine and oxaliplatin chemotherapy
What this could lead to
If successful, this could lead to a more effective pre-surgery treatment for locally advanced rectal cancer, potentially increasing the chance of complete tumor disappearance before surgery.
What could go wrong
This is an early phase 2 trial with only 208 participants, so results may not apply to all patients. The combination of treatments may cause significant side effects, and it is not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••